IN-PULSE

  • Research type

    Research Study

  • Full title

    IN-PULSE: Investigating Neurocognitive and hormone-related Mechanisms of Psychotic vulnerability around Menses and Menopause

  • IRAS ID

    356182

  • Contact name

    Bodyl Brand

  • Contact email

    bodyl.brand@psych.ox.ac.uk

  • Sponsor organisation

    University of Oxford Research Governance, Ethics and Assurance

  • Clinicaltrials.gov Identifier

    000000, 000000

  • Duration of Study in the UK

    4 years, 7 months, 30 days

  • Research summary

    Schizophrenia is a severe psychiatric disorder affecting millions globally. Research indicates that women's vulnerability to psychosis fluctuates with hormonal changes, particularly the female sex hormone oestrogen, which appears to have a protective effect against psychotic symptoms. When oestrogen levels decline, such as during menstruation or menopause, the risk of psychosis episodes increases. Despite this, much of the research on psychosis has focused on men, leaving a significant gap in understanding the impact of hormonal changes on psychosis in women.

    The brain operates through a balance of excitatory and inhibitory signals that regulate cognitive function. Disruptions in this balance, particularly in gamma oscillations (brain waves linked to brain communication), are associated with schizophrenia. Oestrogen decline during the menstrual cycle has been shown to affect gamma oscillations in healthy women, potentially worsening the excitatory/inhibitory (E/I) balance and contributing to the deterioration of the disease. This study seeks to investigate the effects of oestrogen decline on E/I balance in women with schizophrenia and its relation to psychotic vulnerability.

    The focus will be on two key periods: menstruation, when oestrogen levels temporarily drop, and menopause, when oestrogen levels permanently decrease. The study will recruit 90 women with schizophrenia, divided into premenopausal and postmenopausal groups, and compare them to 90 healthy pre- and postmenopausal female controls and 90 age-matched men with schizophrenia. Participants will undergo EEG assessments, neurocognitive tasks, and clinical interviews. For premenopausal women, visits will occur during both high- and low-oestrogen phases of the menstrual cycle.

    By examining differences in brain activity, cognition, and clinical outcomes, the study aims to uncover mechanisms underlying increased psychotic vulnerability in women during low-oestrogen phases, providing insights for improving treatment strategies for women with schizophrenia.

  • REC name

    East Midlands - Nottingham 1 Research Ethics Committee

  • REC reference

    25/EM/0212

  • Date of REC Opinion

    30 Oct 2025

  • REC opinion

    Further Information Favourable Opinion